

Claims:

1. A method of treating a patient having a myocardial infarction comprising administration of a therapeutically effective amount of tissue factor protein antagonist to prevent reocclusion and a thrombolytic agent in a therapeutically effective amount to dissolve a fibrin-platelet clot.
2. A method of treating a patient having angioplasty comprising administration of a therapeutically effective amount of tissue factor protein antagonist to prevent reocclusion and a thrombolytic agent in a therapeutically effective amount to dissolve a fibrin-platelet clot.
3. The method of claim 1 or 2 wherein administration to the patient is by intravenous infusion.
4. The method of claim 1 or 2 wherein administration to the patient is by bolus.
5. The method of claim 4 wherein the bolus is intravenously injected.
6. The method of claim 4 wherein the patient is administered a first bolus containing the tissue factor protein antagonist and subsequently administered a second bolus containing the thrombolytic agent.
7. The method of claim 4 wherein the patient is administered a first bolus containing the thrombolytic agent and subsequently administered a second bolus containing the tissue factor protein antagonist.

8. The method of any one of claims 1 - 4 wherein tissue factor protein antagonist is an antibody.
- 5 9. The method of claim 8 wherein the antibody is a polyclonal antibody.
- 10 10. The method of claim 8 wherein the antibody is a monoclonal antibody.
11. The method of any one of claims 1-4 wherein said thrombolytic agent is selected from the group consisting of streptokinase, urokinase, prourokinase and tissue-type plasminogen activator.
12. The method of claim 11 wherein said thrombolytic agent is tissue-type plasminogen activator.
13. The method of any one of claims 1-3 or 7 wherein the tissue factor protein antagonist is given at a dose of about in the range of 0.01 - 25.0 mg per kg of patient weight and the thrombolytic agent is given at a dose of about in the range of 0.01 - 2.5 mg per kg of patient weight.
14. A pharmaceutical composition for the treatment of myocardial infarction comprising therapeutically effective amounts of a tissue factor protein antagonist and thrombolytic agent.
15. The pharmaceutical composition of claim 14 wherein the tissue factor protein antagonist is an antibody.
16. The pharmaceutical composition of claim 14 wherein the thrombolytic agent is selected from the group consisting of

~~proinflammatory~~
~~prising an~~
~~t in a therap~~

- 5

Sub
A2

[illegible]